1. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.
- Author
-
Song, Ge, He, Wan-Ting, Callaghan, Sean, Anzanello, Fabio, Huang, Deli, Ricketts, James, Torres, Jonathan L, Beutler, Nathan, Peng, Linghang, Vargas, Sirena, Cassell, Jon, Parren, Mara, Yang, Linlin, Ignacio, Caroline, Smith, Davey M, Voss, James E, Nemazee, David, Ward, Andrew B, Rogers, Thomas, Burton, Dennis R, and Andrabi, Raiees
- Subjects
B-Lymphocytes ,Humans ,SARS Virus ,Antibodies ,Viral ,Cross Reactions ,Immunologic Memory ,Female ,Male ,Cross Protection ,Antibodies ,Neutralizing ,Spike Glycoprotein ,Coronavirus ,COVID-19 ,SARS-CoV-2 - Abstract
Pre-existing immunity to seasonal endemic coronaviruses could have profound consequences for antibody responses to SARS-CoV-2, induced from natural infection or vaccination. A first step to establish whether pre-existing responses can impact SARS-CoV-2 infection is to understand the nature and extent of cross-reactivity in humans to coronaviruses. Here we compare serum antibody and memory B cell responses to coronavirus spike proteins from pre-pandemic and SARS-CoV-2 convalescent donors using binding and functional assays. We show weak evidence of pre-existing SARS-CoV-2 cross-reactive serum antibodies in pre-pandemic donors. However, we find evidence of pre-existing cross-reactive memory B cells that are activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, including SARS-CoV-1 and endemic coronaviruses. We identify one cross-reactive neutralizing antibody specific to the S2 subunit of the S protein. Our results suggest that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.
- Published
- 2021